Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2007

Court Permanently Halts Abbott's Sale of HCV Genotyping Products for Infringing Innogenetics' Patent

  • Innogenetics reported that a U.S. court entered a permanent injunction against Abbott Laboratories, prohibiting the company from selling or using products, including components, that infringe on Innogenetics' patented Hepatitis C Virus  genotyping technology. The injunction also prevents Abbott from exporting components of the infringing products to foreign countries.

    In September 2006 a jury unanimously found that Abbott had willfully infringed Innogenetics' U.S. patent 5,846,704 and awarded the company $7 million in damages.

    The U.S. District Court for the Western District of Wisconsin made the ruling at the close of an evidentiary hearing to determine the potential public impact of a permanent injunction against Abbott. Last week, the court found that Innogenetics suffered irreparable harm from Abbott's infringement.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »